Illumina reagents and services

The Florida Department of Health's Bureau of Public Health Laboratories (BPHL) is seeking to procure Illumina MiSeq, iSeq, and NextSeq system reagents and services as a single-source purchase. These instruments and reagents will support BPHL's outbreak detection activities for enteric and viral diseases as required by the Centers for Disease Control and Prevention (CDC). BPHL is requesting authorization to purchase these specialized reagents and services from Illumina, Inc., the sole manufacturer and distributor, for an estimated $6,000,000 over a 3-year term. The required MiSeq, iSeq, and NextSeq system reagents and services are the only CDC-approved kits for testing SARS-CoV-2, HIV, Hepatitis A, TB, and foodborne pathogens. Maintaining continuity with these critical reagents and services is in the best interest of the state. The posting requests information from prospective vendors on their ability to supply the required commodities and services, with a due date of March 19, 2024.

This contract opportunity is limited to Illumina, Inc. as the sole source provider of the required reagents and services. No set-aside designations or restrictions on the types of organizations that can respond are specified. The current incumbent vendor is Illumina, Inc., and the existing infrastructure and technology must be compatible with the Illumina MiSeq, iSeq, and NextSeq systems. The estimated award value is $6,000,000 over a 3-year term.